News articles about Agenus (NASDAQ:AGEN) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Agenus earned a news impact score of 0.16 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.2363689682178 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Agenus (AGEN) opened at $3.65 on Monday. Agenus has a 52 week low of $3.20 and a 52 week high of $5.45. The firm has a market capitalization of $372.17, a price-to-earnings ratio of -3.12 and a beta of 2.10. The company has a current ratio of 1.55, a quick ratio of 1.55 and a debt-to-equity ratio of -2.39.

AGEN has been the topic of a number of recent analyst reports. Zacks Investment Research raised Agenus from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a research note on Tuesday, January 9th. BidaskClub raised Agenus from a “strong sell” rating to a “sell” rating in a research note on Friday. Finally, ValuEngine lowered Agenus from a “sell” rating to a “strong sell” rating in a research note on Friday, December 29th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $5.81.

In other Agenus news, insider Karen Valentine sold 8,358 shares of the stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $3.46, for a total transaction of $28,918.68. Following the transaction, the insider now owns 109,879 shares of the company’s stock, valued at approximately $380,181.34. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In the last three months, insiders have sold 20,514 shares of company stock worth $70,978. Corporate insiders own 7.90% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at

About Agenus

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Insider Buying and Selling by Quarter for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with's FREE daily email newsletter.